TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15650277
Drug: PregVit p.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PregVit p.m. (1 tablet containing 1.1 mg of folic acid) administered in the morning
Study: 15650277
Drug: PregVit p.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PregVit p.m. (1 tablet containing 1.1 mg of folic acid) administered in the evening
Study: 15650277
Drug: PregVit p.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PregVit p.m. (morning administration)
Study: 15650277
Drug: PregVit p.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: PregVit p.m. (evening administration)
Study: 10405497
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg per dose
Study: 10405497
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.6 mg/kg per dose
Study: 7996065
Drug: L-asparaginase
Normalized name: L-asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase
Study: 2374231
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural anesthesia with 0.33 ml.kg.‐1 0.25% bupivacaine before surgery (group A)
Study: 2374231
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural anesthesia with 0.33 ml.kg.‐1 0.25% bupivacaine after surgery (group B)
Study: 6773715
Drug: tocainide 600
Normalized name: tocainide 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tocainide 600 mg three times daily for 8 weeks
Study: 6773715
Drug: quinidine sulfate
Normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quinidine sulfate 300 mg four times daily for 8 weeks
Study: 6773715
Drug: placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered for 6 weeks
Study: 25516371
Drug: Guanfacine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (3 mg/day)
Study: 27146258
Drug: Cholecalciferol 50
Normalized name: cholecalciferol 50 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50 μg (2000 IU) daily
Study: 27146258
Drug: Cholecalciferol 50
Normalized name: cholecalciferol 50 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 50 μg per day
Study: 24661355
Drug: Cholecalciferol 75
Normalized name: cholecalciferol 75000 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 75 μg (3000 IU) daily for 6 months
Study: 18936596
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib 40 mg followed by an additional dose of parecoxib 20 mg
Study: 18936596
Drug: Parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib 20 mg once daily
Study: 18936596
Drug: Parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib 20 mg twice daily
Study: 1653363
Drug: Granisetron (BRL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (BRL 43694A) - single intravenous dose
Study: 6401422
Drug: Balanced substrate
Normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced substrate formula (40 kcal/kg/day, 1 to 1.5 g protein/kg/day, carbohydrate-nitrogen ratio 50:1)
Study: 6401422
Drug: 25% dextrose
Normalized name: Delflex with 4.25% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dextrose and 4.25% protein solution (50 kcal/kg/day, 1 to 1.5 g protein/kg/day, carbohydrate-nitrogen ratio 150:1)
Study: 6401422
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nonseptic patients receiving 25% dextrose and 4.25% protein solution)
Study: 28688174
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of tomato juice (TJ)
Study: 28688174
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL of tomato juice (TJ)
Study: 16972106
Drug: d-amphetamine 15
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 15 mg/70 kg
Study: 17544491
Drug: d-amphetamine 3.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 3.125 mg/70 kg
Study: 16972106
Drug: d-amphetamine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 7.5 mg/70 kg
Study: 17544491
Drug: sublingual estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sublingual estradiol 0.25 mg
Study: 1502481
Drug: Baker's yeast
Normalized name: Baker's yeast proteinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baker's yeast capsules
Study: 6380447
Drug: Trazodone hydrochloride
Normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone hydrochloride (100 mg)
Study: 6380447
Drug: Cocaine hydrochloride
Normalized name: Cocaine Hydrochloride
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine hydrochloride (2 mg/kg)
Study: 20555311
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 mg/day for 7 days)
Study: 8873009
Drug: Thymosin alpha
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha 1 (900 micrograms/m2 of body surface area twice weekly)
Study: 6732217
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of Sch 29,482 orally every 6 h for 4 days
Study: 30669897
Drug: Initial nonoperative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial nonoperative treatment
Study: 25938001
Drug: Temsirolimus 175/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus 175/75 mg
Study: 19415181
Drug: Temsirolimus 75
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus 75 mg
Study: 19825908
Drug: Paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone extended-release 12 mg on days 1-6
Study: 19825908
Drug: Risperidone immediate-release
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone immediate-release 2 mg on day 1 and 4 mg on days 2-6
Study: 18043445
Drug: Pentavalent human-bovine
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent human-bovine (WC3) reassortant rotavirus vaccine
Study: 3544744
Drug: Etretinate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (10 mg capsule once a day)
Study: 29465649
Drug: Metronidazole 750
Normalized name: metronidazole 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 750 mg + miconazole 200 mg intravaginal suppositories for 5 consecutive nights each month for 12 months
Study: 27595688
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without ICD
Study: 24198342
Drug: EMG-triggered electrical
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG-triggered electrical stimulation to the four muscle groups of the affected arm plus usual therapy five times a week for four weeks
Study: 24198342
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy only
Study: 16154196
Drug: Intravitreous pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreous pegaptanib (0.3 mg)
Study: 12190957
Drug: TUDCA (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUDCA (1000 mg)
Study: 12190957
Drug: UDCA (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (750 mg)
Study: 7561189
Drug: Liposome-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome-adjuvanted vaccine
Study: 7561189
Drug: Control subvirion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subvirion vaccine
Study: 647263
Drug: Symptomatic diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic diagnosis and medications
Study: 647263
Drug: No evidence
Approvals — FDA: no, EMA: no, PMDA: no
Description: No evidence of disease and no treatment
Study: 27215528
Drug: Partial stapled
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial stapled transanal rectal resection (part‐STARR) combined with Bresler procedure
Study: 20843951
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 and 20 mg/d)
Study: 20843951
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 and 120 mg/d)
Study: 6397516
Drug: Prostaglandin synthesis
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin synthesis inhibition by indomethacin (150 mg daily for three days plus an additional 50 mg on the morning of the active experiments)
Study: 26572899
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (1 capsule 1 hour before surgery and 1 placebo capsule every 8 hours for 2 days)
Study: 26572899
Drug: Ketorolac 10
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 10 mg (1 capsule 1 hour before surgery and every 8 hours for 2 days)
Study: 25247991
Drug: 12-month maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-month maintenance program consisting of one monthly supervised high intensity interval training session, a written exercise program and exercise diary, and a maximum exercise test every third month during follow-up.
Study: 20103758
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy with hydrocortisone
Study: 20103758
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy with hydrocortisone
Study: 20103758
Drug: Fludrocortisone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone with intensive insulin therapy
Study: 20103758
Drug: Fludrocortisone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone with conventional insulin therapy
Study: 18049323
Drug: Educational interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational interventions for siblings of hospitalized children, conducted by child life specialists, focusing on hospitalization, illness or injury, and treatment.
Study: 9509976
Drug: G‐CSF (Filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (Filgrastim) 5 microg/kg/day starting on day +1 until ANC > 500/microl
Study: 20673585
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G‐CSF)
Study: 7541660
Drug: G‐CSF (Filgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (Filgrastim)
Study: 8092777
Drug: Vaginal prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal prostaglandin E2 gel (1 mg of dinoprostone/2.5 ml gel)
Study: 8092777
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 gel (0.5 mg of dinoprostone in 2.5 ml of two different vehicles)
Study: 8092777
Drug: Prostaglandin gel
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin gel alone
Study: 3402178
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin sodium 100 units/mL flush solution
Study: 3402178
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride flush solution
Study: 30142141
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of Antiretroviral Therapy (ART)
Study: 24691032
Drug: BFR exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFR exercise with rapamycin (RAP) 16 mg administered 1 h prior to exercise
Study: 22111758
Drug: 4.8 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.8 mm diameter implants (test group)
Study: 22111758
Drug: 4.3 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.3 mm diameter implants (control group)
Study: 19809412
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice daily (group A)
Study: 19809412
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily (group B)
Study: 19809412
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg every other day (group C)
Study: 18265809
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific drugs not mentioned)
Study: 18265809
Drug: Cisplatin (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (dosage not specified)
Study: 18265809
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy (specific drugs not mentioned)
Study: 18265809
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for patients with brain metastases
Study: 18265809
Drug: Specific drugs
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific drugs for patients with bone metastases
Study: 1214706
Drug: Alice strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alice strain vaccine (AS) intranasally
Study: 23660095
Drug: Anti-infection therapy
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-infection therapy within 1 hour after admission (Observation group)
Study: 23660095
Drug: Anti-infection therapy
Normalized name: gentian violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-infection therapy 1-6 hours after admission (Control group)
Study: 18674411
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules (3-12 mg/day)
Study: 18200818
Drug: Angiotensin‐II receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐II receptor blockers (ARBs)
Study: 18200818
Drug: Angiotensin‐converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin‐converting enzyme (ACE) inhibitors
Study: 18200818
Drug: Calcium‐channel blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐channel blockers (CCBs)
Study: 18595261
Drug: Beta‐blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta‐blockers
Study: 15109470
Drug: Pretravel brochures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretravel brochures explaining the hazards of drug abuse
Study: 15109470
Drug: Overall drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall drug use
Study: 11687449
Drug: Full-dose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose (10 microg of PRP antigen)
Study: 11687449
Drug: One-half dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-half dose (5.0 microg of PRP antigen)
Study: 11687449
Drug: One-third dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-third dose (3.3 microg of PRP antigen)
Study: 9744695
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA)/non‐steroidal anti‐inflammatory drug (NSAID) intake before admission
Study: 26386123
Drug: Axitinib/BSC (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib/BSC (5 mg twice-daily)
Study: 23354535
Drug: B. monniera
Approvals — FDA: no, EMA: no, PMDA: no
Description: B. monniera (Brahmi) extract 450 mg
Study: 22214254
Drug: L-theanine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (400 mg daily, 100 mg per tablet, two tablets twice daily)
Study: 22214254
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tasting chewable tablets)
Study: 22214254
Drug: L-theanine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (400 mg daily)
Study: 19201576
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy (Bifidobacterium longum 2 x 10(9) CFU daily)
Study: 19201576
Drug: Prebiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic therapy (8.0 g of psyllium daily)
Study: 19201576
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy (both probiotic and prebiotic treatments)
Study: 15884251
Drug: 50 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/day of continuous transdermal estradiol with sequential transdermal norethisterone acetate (NETA) in daily doses of 170 micrograms in a single transdermal patch
Study: 10659551
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation (Sara, Thai Nakorn Patana)
Study: 1716790
Drug: Desmopressin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.3 micrograms/kg BW i.v.) + Dextran 70 (30 g i.v.)
Study: 1716790
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (30 g i.v.)
Study: 6644348
Drug: 5 X
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 X 10(6) U/m2 weekly
Study: 29490577
Drug: Medium-whey-protein (22 g·L‐1)
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-whey-protein (22 g·L‐1) CE drink (CW‐M)
Study: 29490577
Drug: High-whey-protein (33 g·L‐1)
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-whey-protein (33 g·L‐1) CE drink (CW‐H)
Study: 29490577
Drug: Low-carbohydrate CE
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate CE drink (CE‐L)
Study: 27161620
Drug: Intensive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive antihypertensive therapy (systolic BP <120 mm Hg)
Study: 27161620
Drug: Standard antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antihypertensive therapy (systolic BP <140 mm Hg)
Study: 22613901
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 or 10 mg/kg)
Study: 22613901
Drug: Immunomodulator treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulator treatment (vs. treatment without immunomodulator) in UC patients
Study: 22613901
Drug: Infliximab or
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab or immunomodulator treatment
Study: 20146676
Drug: 3‐4 component
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐4 component therapy plus SCUF or CVVHF
Study: 10582669
Drug: Permanent low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent low dose-rate I-125 seeds placement after resection
Study: 8727171
Drug: Besipirdine 5
Normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besipirdine 5 mg b.i.d.
Study: 8727171
Drug: Besipirdine 20
Normalized name: Nerispirdine
DrugBank: Nerispirdine (DB12714)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Besipirdine 20 mg b.i.d.
Study: 8727171
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (combined besipirdine doses)
Study: 8727171
Drug: Post-treatment assessment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment assessment
Study: 1744753
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program consisting of three sessions led by a specially trained RN, focusing on medication compliance, attack prevention, drug effects, relaxation exercises, and smoking cessation.
Study: 7064898
Drug: 500 kcal
Normalized name: inf.formula,urea cycle disordr 6.5 gram-500 kcal/100 gram ORAL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 kcal 55 g protein natural food
Study: 27649903
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and Acceptance-based Group Therapy (MAGT)
Study: 27064996
Drug: Once-daily abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily abacavir + lamivudine
Study: 27064996
Drug: Twice-daily abacavir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily abacavir + lamivudine
Study: 15330012
Drug: Chiropractic spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic spinal manipulative therapy (SMT)
Study: 20061012
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Act d 1, Act d 2, Act d 4, and Act d 5
Study: 3947525
Drug: Salbutamol nebulized
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulized at 4 litres/min (1 mg)
Study: 3947525
Drug: Salbutamol nebulized
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulized at 8 litres/min (5 mg)